[go: up one dir, main page]

PL3668860T3 - Formy soli cholinowej inhibitora kapsydu wirusa hiv - Google Patents

Formy soli cholinowej inhibitora kapsydu wirusa hiv

Info

Publication number
PL3668860T3
PL3668860T3 PL18778575T PL18778575T PL3668860T3 PL 3668860 T3 PL3668860 T3 PL 3668860T3 PL 18778575 T PL18778575 T PL 18778575T PL 18778575 T PL18778575 T PL 18778575T PL 3668860 T3 PL3668860 T3 PL 3668860T3
Authority
PL
Poland
Prior art keywords
salt forms
choline salt
hiv capsid
capsid inhibitor
inhibitor
Prior art date
Application number
PL18778575T
Other languages
English (en)
Inventor
Travis Lee Houston
Bing Shi
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3668860T3 publication Critical patent/PL3668860T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18778575T 2017-08-17 2018-08-16 Formy soli cholinowej inhibitora kapsydu wirusa hiv PL3668860T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546974P 2017-08-17 2017-08-17
EP18778575.3A EP3668860B1 (en) 2017-08-17 2018-08-16 Choline salt forms of an hiv capsid inhibitor
PCT/US2018/000248 WO2019035973A1 (en) 2017-08-17 2018-08-16 CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR

Publications (1)

Publication Number Publication Date
PL3668860T3 true PL3668860T3 (pl) 2022-04-25

Family

ID=63684411

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21217553.3T PL4046994T3 (pl) 2017-08-17 2018-08-16 Formy soli cholinowej inhibitora kapsydu wirusa hiv
PL18778575T PL3668860T3 (pl) 2017-08-17 2018-08-16 Formy soli cholinowej inhibitora kapsydu wirusa hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21217553.3T PL4046994T3 (pl) 2017-08-17 2018-08-16 Formy soli cholinowej inhibitora kapsydu wirusa hiv

Country Status (14)

Country Link
US (4) US10849892B2 (pl)
EP (3) EP3668860B1 (pl)
JP (2) JP6933770B2 (pl)
KR (2) KR102497604B1 (pl)
CN (2) CN117285513A (pl)
AR (1) AR112412A1 (pl)
AU (1) AU2018317304B2 (pl)
CA (1) CA3070154A1 (pl)
ES (2) ES2906385T3 (pl)
PL (2) PL4046994T3 (pl)
PT (1) PT3668860T (pl)
SI (1) SI3668860T1 (pl)
TW (2) TW202030187A (pl)
WO (1) WO2019035973A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
HUE063811T2 (hu) 2016-08-19 2024-02-28 Gilead Sciences Inc HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175384A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP4234561A3 (en) * 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020154656A1 (en) 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2021108544A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
MX2022011016A (es) 2020-03-06 2022-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TWI858267B (zh) * 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202412779A (zh) 2021-12-03 2024-04-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CN115607505A (zh) * 2022-11-01 2023-01-17 上海复星医药产业发展有限公司 一种阿兹夫定口服制剂及制备方法和应用
EP4615461A1 (en) * 2022-11-11 2025-09-17 Intercept Pharmaceuticals, Inc. Crystalline forms of a farnesoid x receptor agonist
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
WO2024237331A1 (ja) * 2023-05-17 2024-11-21 オンコリスバイオファーマ株式会社 フェナントリジノン誘導体のコリン塩
AU2024281548A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
WO2024249672A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Process of preparing hiv capsid inhibitor
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025240391A2 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240393A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240389A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240385A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5100518A (en) 1990-12-20 1992-03-31 At&T Bell Laboratories Method and apparatus for plating insulating strip
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
AU2002316437A1 (en) 2001-06-27 2003-03-03 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
BRPI0508186A (pt) 2004-02-27 2007-08-14 Schering Corp compostos como inibidores de ns3 serina protease de vìrus da hepatite c
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 ｘｉａ 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
PL2010493T3 (pl) 2006-04-12 2016-08-31 Merck Sharp & Dohme Pirydyloamidy jako antagoniści kanałów wapniowych typu t
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
EP2139883A4 (en) 2007-03-23 2011-06-22 Univ Massachusetts HIV-1 protease inhibitor
JP5465667B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
JP2012518431A (ja) 2009-02-25 2012-08-16 ビッグテック プライベート リミテッド チクングニア検出用のプローブおよびプライマー
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
BR112012003703A2 (pt) 2009-08-18 2020-12-08 Ventrix Phramaceuticals, INC. Benzoazepinas substituídas como moduladores do receptor tipo toll
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
PH12013500015A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
CN103458902B (zh) 2010-10-01 2017-11-07 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
MX351464B (es) 2010-10-01 2017-10-16 Ventirx Pharmaceuticals Inc Star El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CN106518851A (zh) 2011-01-12 2017-03-22 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN103562186B (zh) 2011-01-12 2017-02-15 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
EP3872076A1 (en) 2011-03-23 2021-09-01 Trevena, Inc. Opioid receptor ligands and methods of using and making same
PL2694484T3 (pl) 2011-04-08 2019-02-28 Janssen Sciences Ireland Uc Pochodne pirymidyny do leczenia zakażeń wirusowych
EA024952B1 (ru) 2011-04-21 2016-11-30 Джилид Сайэнс, Инк. Бензотиазолы и их применение для лечения вич-инфекции
PL2709989T3 (pl) 2011-05-18 2018-06-29 Janssen Sciences Ireland Uc Pochodne chinazoliny do leczenia infekcji wirusowych i dalszych chorób
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EA027768B1 (ru) 2011-08-16 2017-08-31 Джилид Сайэнс, Инк. Тенофовир алафенамида гемифумарат
WO2013091096A1 (en) * 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
ES2716811T3 (es) 2012-02-08 2019-06-17 Janssen Sciences Ireland Unlimited Co Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas
EP2822560A1 (en) 2012-03-05 2015-01-14 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
RU2014115227A (ru) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
KR102216479B1 (ko) * 2012-08-10 2021-02-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 또는 추가 질환의 치료를 위한 알킬피리미딘 유도체
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
AU2013328732B2 (en) * 2012-10-10 2017-08-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MY171115A (en) * 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (en) 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
US9012441B2 (en) 2013-01-09 2015-04-21 Gilead Sciences, Inc. Therapeutic compounds
WO2014110323A1 (en) 2013-01-11 2014-07-17 Johnson Controls Technology Company Vehicle interior component having a wireless charging indicator
EA035174B1 (ru) * 2013-02-21 2020-05-12 Янссен Сайенсиз Айрлэнд Юси Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
SG11201603217SA (en) 2013-10-24 2016-05-30 Bristol Myers Squibb Co Inhibitors of human immunodeficiency virus replication
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
AU2015308907B2 (en) 2014-08-29 2018-10-18 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
MX2017008520A (es) 2014-12-24 2018-03-01 Gilead Sciences Inc Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
HUE038059T2 (hu) 2015-03-04 2018-10-29 Gilead Sciences Inc Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
AR104388A1 (es) 2015-04-23 2017-07-19 Bristol Myers Squibb Co Inhibidores de la replicación del virus de la inmunodeficiencia humana
KR20180005195A (ko) 2015-04-23 2018-01-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
SG11201702041PA (en) 2015-07-06 2017-04-27 Gilead Sciences Inc Cot modulators and methods of use thereof
HUE063811T2 (hu) * 2016-08-19 2024-02-28 Gilead Sciences Inc HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175384A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2021108544A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑

Also Published As

Publication number Publication date
TW201920142A (zh) 2019-06-01
WO2019035973A8 (en) 2020-01-23
CA3070154A1 (en) 2019-02-21
EP4046994A1 (en) 2022-08-24
EP4046994C0 (en) 2024-02-21
TW202030187A (zh) 2020-08-16
US20240245669A1 (en) 2024-07-25
JP2020531429A (ja) 2020-11-05
AU2018317304A1 (en) 2020-02-06
US20190083478A1 (en) 2019-03-21
SI3668860T1 (sl) 2022-04-29
WO2019035973A1 (en) 2019-02-21
EP3668860B1 (en) 2022-01-05
KR20200039762A (ko) 2020-04-16
US11833143B2 (en) 2023-12-05
KR102497604B1 (ko) 2023-02-08
KR102389850B1 (ko) 2022-04-22
US20220249460A1 (en) 2022-08-11
PL4046994T3 (pl) 2024-06-24
JP6933770B2 (ja) 2021-09-08
US11266638B2 (en) 2022-03-08
AR112412A1 (es) 2019-10-23
EP3668860A1 (en) 2020-06-24
EP4046994B1 (en) 2024-02-21
CN117285513A (zh) 2023-12-26
ES2906385T3 (es) 2022-04-18
AU2018317304B2 (en) 2020-11-05
ES2977959T3 (es) 2024-09-03
US20200397772A1 (en) 2020-12-24
PT3668860T (pt) 2022-04-14
EP4382105A3 (en) 2024-08-14
KR20220054706A (ko) 2022-05-03
EP4382105A2 (en) 2024-06-12
TWI693219B (zh) 2020-05-11
JP2021178873A (ja) 2021-11-18
US10849892B2 (en) 2020-12-01
CN111051297A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
PL4046994T3 (pl) Formy soli cholinowej inhibitora kapsydu wirusa hiv
PL3668859T3 (pl) Stałe postacie inhibitora kapsydu HIV
ZA201801417B (en) Salts of an lsd1 inhibitor
ZA201807865B (en) Formulations of an lsd1 inhibitor
ZA201604272B (en) Inhibitors of glutaminase
IL252756A0 (en) solid forms of ask1 inhibitor
IL257061A (en) Inhibitors of ezh2
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
ZA201904460B (en) Inhibitors of nhe-mediated antiport
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL262111B1 (en) Monovalent inhibitors of hutnfr1 interaction
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
SG10202103332UA (en) Solid forms of ttk inhibitor
HK40109498A (en) Choline salt forms of an hiv capsid inhibitor
HK40099486A (en) Choline salt forms of an hiv capsid inhibitor
HK40117529A (en) Solid forms of an hiv capsid inhibitor
HK40100506A (en) Solid forms of an hiv capsid inhibitor
HK1228907A1 (en) Novel inhibitors of glutaminase